Biotech M&A Wave Positions SBIO for Growth | ETF TrendsETF Trends is now VettaFi. Read More --The biotech M&A market is heating up as pharmaceutical companies confront a looming patent cliff that will strip $200 billion to $250 billion in branded medicine sales by 2032, according to an ING [report] published in January. As patents expire on blockbuster drugs, cheaper generic versions can enter the market and slash revenue for the original drugmakers.The research projects both the number of acquisitions and ...